SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-023877
Filing Date
2022-11-09
Accepted
2022-11-09 16:17:03
Documents
73
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q qncx-20220930.htm   iXBRL 10-Q 3827522
2 EX-10.1 qncx-ex10_1.htm EX-10.1 99247
3 EX-31.1 qncx-ex31_1.htm EX-31.1 17776
4 EX-31.2 qncx-ex31_2.htm EX-31.2 17735
5 EX-32.1 qncx-ex32_1.htm EX-32.1 13656
6 EX-32.2 qncx-ex32_2.htm EX-32.2 13646
  Complete submission text file 0000950170-22-023877.txt   13098908

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT qncx-20220930_cal.xml EX-101.CAL 52683
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT qncx-20220930.xsd EX-101.SCH 53785
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT qncx-20220930_lab.xml EX-101.LAB 481122
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT qncx-20220930_def.xml EX-101.DEF 211654
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT qncx-20220930_pre.xml EX-101.PRE 366526
67 EXTRACTED XBRL INSTANCE DOCUMENT qncx-20220930_htm.xml XML 2942110
Mailing Address 601 GATEWAY BOULEVARD, SUITE 1250 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 1250 SOUTH SAN FRANCISCO CA 94080 415-910-5717
Quince Therapeutics, Inc. (Filer) CIK: 0001662774 (see all company filings)

IRS No.: 901024039 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38890 | Film No.: 221372857
SIC: 2836 Biological Products, (No Diagnostic Substances)